Actinium Pharmaceuticals Inc (ATNM) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $1.16
• Market Cap: $35.56M
• EPS: $-1.18
• 52-Week High: $2.41
• 52-Week Low: $1.02

Market Sentiment

Actinium Pharmaceuticals Inc currently has a Neutral sentiment score of 0.03.

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborati...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Actinium Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ATNM pay dividends?

Actinium Pharmaceuticals Inc (ATNM) does not currently pay a regular dividend.

What is ATNM's market cap?

Actinium Pharmaceuticals Inc (ATNM) has a market capitalization of $35.56M with a current stock price of $1.16.